442 material Form 8-K filings that 386 companies we cover made with the SEC in March 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
First Industrial Realty Trust amended and restated its revolving credit facility, raising borrowing capacity from $750.0 million to $850.0 million and extending maturity to March 16, 2029. It also refinanced its $200.0 million unsecured term loan, extending its maturity to March 17, 2028, with lower pricing spreads and longer extension options. The changes add liquidity and push out debt maturities, though the filing reports no change to earnings or guidance.
Revolving facility increased from $750.0 million to $850.0 million, with an accordion feature to $1.0 billion
Revolver maturity extended from July 7, 2025 to March 16, 2029; term loan maturity extended from July 7, 2026 to March 17, 2028
Revolver had $431.0 million outstanding; applicable margin set at 0.775% based on BBB/Baa2/BBB ratings
Company has fully and unconditionally guaranteed borrowings under both agreements
Liquidia Technologies, a wholly owned subsidiary of Liquidia Corporation, signed a Sixth Amendment to its Revenue Interest Financing Agreement with HealthCare Royalty Partners IV on March 17, 2025, adding up to $100 million in financing in three tranches. The company received $25.0 million at the effective date, with the remaining tranches tied to YUTREPIA commercial milestones. Repayments are capped at 175% of amounts advanced and follow a fixed schedule ending in 2032, so the added funding comes with a defined repayment obligation.
$25.0 million funded on the March 17, 2025 effective date
$50.0 million to be funded after the first commercial sale of YUTREPIA following final FDA approval for PAH and PH-ILD, absent an injunction
$25.0 million to be funded by mutual agreement if aggregate YUTREPIA net sales exceed $100 million on or before June 30, 2026
Aggregate payments capped at 175% of amounts advanced; fixed payment schedule terminates in 2032
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.